2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
Executive Summary
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.